Combining Multiple Approaches for the Secondary Prevention of Vascular Events After Stroke
Top Cited Papers
- 1 June 2007
- journal article
- research article
- Published by Wolters Kluwer Health in Stroke
- Vol. 38 (6), 1881-1885
- https://doi.org/10.1161/strokeaha.106.475525
Abstract
Numerous effective strategies for the secondary prevention of cardiovascular events in high-risk patients have now been established. We sought to calculate the cumulative benefit of combining multiple strategies for preventing recurrent events in patients with a history of ischemic stroke or transient ischemic attack. A comprehensive literature search was undertaken to identify meta-analyses of randomized controlled trials reporting on the efficacy of secondary prevention strategies. The baseline incidence of vascular events was modeled from the Life Long After Cerebral Ischemia study. Strategies were combined on a multiplicative scale and cumulative risk reductions were computed over a 5-year interval. The combination of 5 proven strategies applied to survivors of an initial stroke or transient ischemic attack--dietary modification, exercise, aspirin, a statin, and an antihypertensive agent--could result in a cumulative relative risk reduction of 80%. Given a 5-year major cardiovascular event rate of 24%, this translates to a number needed to treat of about 5. Further gains would result from applying multimodality therapy over longer intervals and enriching the base strategy with dual antiplatelet therapy, high-dose statins, and more intensive blood pressure-lowering. Even more benefit would be present in high-risk subgroups with the addition, where appropriate, of carotid endarterectomy, moderate intensity oral anticoagulants, glycemic control, and smoking cessation. At least four-fifths of recurrent vascular events in patients with cerebrovascular disease might be prevented by application of a comprehensive, multifactorial approach.Keywords
This publication has 32 references indexed in Scilit:
- Meta-Analysis of Cardiovascular Outcomes Trials Comparing Intensive Versus Moderate Statin TherapyJournal of the American College of Cardiology, 2006
- Angiotensin-converting-enzyme inhibitors in stable vascular disease without left ventricular systolic dysfunction or heart failure: a combined analysis of three trialsThe Lancet, 2006
- Global and regional burden of disease and risk factors, 2001: systematic analysis of population health dataThe Lancet, 2006
- Risk of Myocardial Infarction and Vascular Death After Transient Ischemic Attack and Ischemic StrokeStroke, 2005
- Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statinsThe Lancet, 2005
- Endarterectomy for symptomatic carotid stenosis in relation to clinical subgroups and timing of surgeryThe Lancet, 2004
- Additive Benefits of Pravastatin and Aspirin to Decrease Risks of Cardiovascular DiseaseArchives of Internal Medicine, 2004
- Effects of a Perindopril-Based Blood Pressure–Lowering Regimen on the Risk of Recurrent Stroke According to Stroke Subtype and Medical HistoryStroke, 2004
- MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trialThe Lancet, 2002
- Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patientsBMJ, 2002